with bevacizumab with an average age of 62 (ranging 45–79). 40 treatments were reviewed (one patient received two different bevacizumab regimens during the monitoring process), 42.5% of which followed the indications authorised by the EMA. The regimens that didn’t fit to the technical data (57.5%) were as follows: 46% bevacizumab in monotherapy 15 mg/kg/21 days, 54% bevacizumab associated with other cytostatics different from paclitaxel or capetitabine. Combinations with bevacizumab not indicated in the technical data were: 37% bevacizumab 15 mg/kg + liposomal doxorubicin 75 mg/m²/21 days, 37% bevacizumab 15 mg/kg/21 days + vinorelbine 25 mg/m² days 1 and 8, 10% bevacizumab 15 mg/kg/21 days, 10% bevacizumab 10 mg/kg + introtesan to 125 mg/m²/15 days and 6% bevacizumab 15 mg/kg + docetaxel 100 mg/m²/21 days.

Conclusions Despite the extension of the bevacizumab indications in 2011 by the European Medicines Agency (EMA) the off-label use of bevacizumab remains high, probably due to the clinical evidence with bevacizumab, which has evolved rapidly in recent years. In this sense, the importance of pharmacists’ role should be stressed in evaluating the use of medicine in relation to the recent evidence of the MBC.

No conflict of interest.

**GRP-179** SURFACE CONTAMINATION WITH ANTI NEOPLASTIC DRUGS IN SEVEN FRENCH HOSPITAL PHARMACIES

doi:10.1136/ejhpharm-2013-000276.179

1UMF L3, D Pradeau, P Prognon, E Caudron. ‘Hospital Européen Georges Pompidou, Pharmacy, Paris, France; 2Pharmaceutical Establishment of Paris Hospitals, Analytical Development Laboratory, Paris, France

Background Due to their carcinogenic, mutagenic and teratogenic properties, handling cytotoxic drugs presents a risk of occupational exposure for healthcare workers.

Purpose To evaluate and limit occupational risk, environmental monitoring was conducted in 7 French hospital pharmacies that prepare formulations of carboplatin, cisplatin and oxaliplatin. Platinum was used as the tracer (~20% of the production).

Materials and Methods From 2010 to 2012, 7 cytotoxic drug preparation units were investigated. Different types of surface were evaluated: the external surface of vials containing cytotoxic materials, workplace surfaces and the surfaces of antineoplastic drug preparations. Surfaces were sampled with a moistened swab. After pre-concentration by cloud point extraction, the quantity of elemental platinum was evaluated by graphite furnace atomic absorption spectrometry. The lower limit of detection corresponded to 2 ng of platinum per sample.

Results A total of 518 samples analysed had various levels of contamination and we found a frequency of cytotoxic contamination of more than 57% of samples (>2 ng). Contamination was found on 58% of vials of cisplatin, carboplatin and oxaliplatin from different manufacturers (n = 111, mass 66 ng), 56% of cytotoxic preparations (n = 18, mass 78 ng) with 29% of packagings (n = 24, mass 15 ng) and 56% of workplace surfaces (n = 365) contaminated. Surfaces inside isolators were the most contaminated area (59%, n=169) compared with storage areas (28%, n = 89), controlled areas (15%, n = 55), control laboratories (24%, n = 25) and other areas (4%, n = 27). However the highest level of contamination was found inside storage boxes of vials containing cytotoxics with more than 20,000 ng of Pt.

Conclusions Regarding environmental monitoring, two major sources of contamination were identified: the outer surface of vials of cytotoxic material and handling cytotoxic drugs inside the isolator. Other contamination spreads from those initial points of contamination. Thus, it seems necessary to use effective individual protective equipment but also to use efficient cleaning protocols to limit chemical contamination and thus, to prevent occupational exposure.

No conflict of interest.

**GRP-179** SWITCH FROM CERA TO EPO ZETA IN PATIENTS WITH ANAEMIA AND CHRONIC KIDNEY DISEASE

doi:10.1136/ejhpharm-2013-000276.179

1L Perani, C Scolari, A Bras, E Galli. General Hospital of Treviglio Caravaggio, Pharmacy Unit, Treviglio (BG), Italy; 2General Hospital of Treviglio Caravaggio, Nephrology Department, Treviglio (BG), Italy

Background As the result of a possible shortage of methoxy polyethylene glycol epoetin beta (CERA) within Italy, with the agreement of the EMA, AIFA (the Italian Medicines Agency) prepared a document inviting prescribers to switch patients who were undergoing treatment with different doses of CERA to any Erythropoiesis Stimulating Agent (ESA), for the treatment of anaemia associated with chronic kidney disease (CKD).

This recommendation emphasised the need to monitor haemoglobin levels (Hb) and safety and efficacy parameters.

Purpose To evaluate variations of efficacy (Hb levels) and safety (immunological reaction) of a new treatment, in patients with CKD after switching from CERA to epoetin zeta (EPO zeta), as per international and national guidelines.

To keep the same Hb level obtained before the shift.

To compare the cost differences of the two ESAs.

Materials and Methods A preliminary observational study (April–September 2012) was carried on CKD patients in haemodialysis care at the Department of Nephrology. The patients enrolled were treated with some of the doses of CERA indicated in the Recommendation for at least ten months. We evaluated ESA dosage, Hb level and dosage/kg.

Results The study included 12 patients (7 men and 5 women) with mean age 56.64 years (range 40–75). All patients were treated with EPO zeta (average initial dose 6500 IU/Kg/week); after monthly monitoring of Hb levels, the initial dose of EPO zeta was increased by 7.69% (average dose 7000 IU/Kg/week) and three months later, the median Hb level observed was 11.38 g/dl.

Statistical analysis showed no significant difference between CERA and EPO zeta in terms of Hb level (P = 0.408).

No adverse events due to treatment were recorded; no variation in iron supplementation.

The use of EPO zeta resulted in savings of 250 euro per month/patient versus CERA treatment.

Conclusions After switching from CERA therapy, the use of EPO zeta appears effective and safe for CKD patient treatment. Data showed the need to increase the dose of EPO zeta to maintain a steady Hb level. Despite the increased consumption, the use of this biosimilar could contribute to containing pharmaceutical costs.

No conflict of interest.

**A64** TELAPREVI AND BOCEPREVI: SAFETY AND EFFICACY OF THE INITIAL TREATMENTS IN THE HOSPITAL

doi:10.1136/ejhpharm-2013-000276.180

A Valle Díaz de la Guardia, C García Fernández, C Gómez Peña, J Cabeza Barrera. Hospital Universitario San Cecilio, Farmacia Hospitalaria, Granada, Spain

Background These novel treatments for hepatitis C have been recently approved in Spain. Several studies have confirmed their great efficiency in achieving good virological response.

Purpose To present the preliminary results of treatment with these drugs in a 600-bed hospital and find the adherence of patients to triple treatment: ribavirin, peginterferon and boceprevir or telaprevir.

No conflict of interest.
Materials and Methods All patients treated with telaprevir or boceprevir since its inclusion in the hospital (January 2012) were included. We studied the medical records to see if patients were treatment-naive or a previously treated, and we checked the occurrence of adverse reactions associated with antiviral treatment. To calculate the adherence, dispensing records from the Pharmacy Service were used and percentage adherence was calculated. The primary end point was the rate of rapid virological response at week 4 for patients who completed one month of treatment and at week 12 for patients who completed three months. We used a formula for calculating percentage adherence, stating that a patient was adherent if treatment intake exceeded 95%.

Results At the time of the study (June 2012), 8 patients were treated with telaprevir (‘T group’) and 6 with boceprevir (‘B group’). In the T group there were 2 treatment-naive patients and 6 with no response to previous treatment. All patients who completed three months of treatment (4 patients) achieved rapid virological response. The other 4 patients completed one month of treatment and in all of them HCV RNA was undetectable at week 4. Pruritus and eczema were the most common adverse reactions in group T (in 90% of patients). In the B group, there were 3 treatment-naive patients and 3 previously treated. Four patients completed three months of triple treatment, but one of them did not reach rapid virological response. Regarding the 2 patients who completed one month of treatment, only one patient had undetectable HCV RNA at week 4. There were no adverse reactions related to boceprevir in this group. Patients of both groups were adherent to treatment.

Conclusions The addition of boceprevir or telaprevir to standard treatment increased the rates of rapid virological response, treatment-naive and previously treated patients. The role of the Pharmacy Service is very important in promoting patient adherence despite the adverse effects that may occur.

No conflict of interest.

**GRP-182** The clinical pharmacist’s impact on the appropriate use of medicines in elderly patients

doi:10.1136/eurjhp-2013-000276.182

1F Arnaud, 1F Dubois, 1M Soulair, 1C Knight, 1M Knight, 1C Roux, 1JM Kinowski. CHU Carêmeau, Pharmacy, Nimes cedex 9, France; 1AFSSAPS, Hospital preparations, Paris, France

Background Adverse effects caused by the treatment are frequent in the elderly and most often result from an inappropriate prescription. Experts have published a list of potentially inappropriate medicines for the elderly (aged 75 and over) [1].

Purpose To measure the clinical pharmacist’s impact on compliance with this reference work.

Materials and Methods Our study was carried out in two units, the infectious and tropical diseases unit (SMIT) and a multipurpose medicine unit (MEPO) over a 1.5-month period. Drug prescriptions for patients aged 75 and over were analysed in the units after medicines reconciliation by the clinical pharmacist. Conformity with the list of potentially inappropriate medicines (MPIs) was assessed on the optimised medical record (BMO) and the hospital prescription entry. The list of MPIs was divided into three categories of treatment: unfavourable risk/benefit ratio (type 1), questionable effectiveness (type 2) and unfavourable risk/benefit ratio and questionable effectiveness (type 3). When an inappropriate medicine was prescribed, the clinical pharmacist suggested interruption or alternative treatments.

Results Medicines reconciliation was conducted on 32 patients aged 75 and over in the two units (9 in SMIT and 23 in MEPO). Description of these MPIs was: 54.5% for type 1, 18.3% for type 2 and 27.2% for type 3. Medicines were stopped (54.5%), switched (18.2%) or continued (27.3%).

Conclusions We found more at-risk patients in MEPO than in the SMIT. In 27.3% of cases, treatments were continued after consulting the doctor and reassessing the risk/benefit ratio and effectiveness. In 72.7% of cases the clinical pharmacist’s contribution led to stopping or switching the MPI, confirming his essential role in the compliance with standards.

Reference


No conflict of interest.